Roche Diagnostics Introduces Endotrophin Assay Prototype at Nordic Bioscience Lab

Introduction


In an exciting development for research in cardiovascular and kidney diseases, Roche Diagnostics has announced the availability of its Endotrophin (ETP) research prototype assay at Nordic Bioscience's CLIA lab. This innovative assay is designed for use on the cobas® e801 analyzers, marking a significant step forward in the field of biomarker development.

What is Endotrophin?


Endotrophin is a 77-amino-acid pro-peptide that gets released during the synthesis of type VI collagen. Known for its association with various diseases, including fibrosis, inflammation, and adverse outcomes in cardiovascular, kidney, and metabolic conditions, it plays a crucial role in signaling within the body.

The Importance of ETP Assay


The newly launched assay is a sandwich immunoassay that quantifies Endotrophin hormone levels effectively. Research indicates that elevated levels of Endotrophin are closely linked to increased mortality and negative health outcomes, particularly in patients suffering from heart failure with preserved ejection fraction (HFpEF). Acknowledging this, the FDA has shown support for using Endotrophin in further research aimed at enriching clinical trials for HFpEF.

Clinical Impact and Research Validations


Over 50,000 patients with cardio-kidney-metabolic disease have had their Endotrophin levels measured, providing a robust database for understanding its implications in clinical settings. Notably, in chronic kidney disease, heightened levels of Endotrophin correlate with disease severity and could serve as a prognostic marker for declines in kidney function. Moreover, research efforts have established causal relationships linking Endotrophin levels to coronary artery disease, highlighting its potential as an invaluable tool in cardiometry and nephrometry.

Why is It a Game Changer?


Morten Karsdal, CEO of Nordic Bioscience, emphasized the promising potential of Endotrophin by stating, "Endotrophin may be the best biomarker for the cardio-renal syndrome. However, it is more than just a biomarker; it represents a therapeutic target. We envision it as the next significant advancement similar to TNF-alpha." Such insights illuminate the path forward for medical research toward innovative treatments and interventions.

Looking Ahead


As Endotrophin continues to be explored in clinical trials, its role as a biomarker is increasingly recognized. Future studies will not just examine its predictive capabilities but aim to utilize it in therapeutic contexts, shedding light on profound insights yet to be uncovered.

In conclusion, the collaboration between Roche Diagnostics and Nordic Bioscience stands as a promising frontier in healthcare diagnostics, which could transform patient care in domains heavily burdened by fibrosis and inflammation-related diseases.

About Nordic Bioscience


Based in Herlev, Denmark, Nordic Bioscience specializes in the development of biomarkers, particularly those connected to the extracellular matrix (ECM). Their innovative neoepitope platform technology allows for precision in biomarker development, aimed at enhancing decision-making in clinical trials and offering valuable diagnostics for patients. For more information, visit Nordic Bioscience.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.